DURECT grants worldwide rights of SABER ophthalmology product to Santen
As part of the deal, DURECT will receive an upfront fee of $2m in cash from Santen as well as reverie contingent cash payments upon the achievement of
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
The approval was based on demonstration of improved progression-free survival (PFS) in a 96-week Phase III trial called CLARINET. The multi-center, international, randomized, double-blind, placebo-controlled trial enrolled a
Backed by funding of €15.1m from the European Commission (EC), the new consortium includes GSK and research partners from University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne
Signifor LAR is a somatostatin analog (SSA) administered intramuscularly once-monthly, which exerts its pharmacological activity through binding to somatostatin receptors (SSTRs). Novartis Oncology president Bruno Strigini said: "The